{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:10Z","timestamp":1790694070050,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03620-w","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:37:22Z","timestamp":1790692642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective observational study of treatment sequencing with regorafenib and FTD\/TPI in metastatic colorectal cancer: The OSERO study"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9516","authenticated-orcid":false,"given":"Takeshi","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsutaro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1894-4113","authenticated-orcid":false,"given":"Akihiko","family":"Chida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-8741","authenticated-orcid":false,"given":"Seiichiro","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5563-5802","authenticated-orcid":false,"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-8536","authenticated-orcid":false,"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-2765","authenticated-orcid":false,"given":"Kentaro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-9507","authenticated-orcid":false,"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-0379","authenticated-orcid":false,"given":"Shogen","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kashiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-8453","authenticated-orcid":false,"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3142-6164","authenticated-orcid":false,"given":"Ayumu","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-4739","authenticated-orcid":false,"given":"Keiji","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-6803","authenticated-orcid":false,"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2039-3062","authenticated-orcid":false,"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"3620_CR1","unstructured":"International Agency for Research on Cancer, Cancer Today: estimated number of new cancer cases, all sexes, https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/bars?mode=population&cancers=41&populations=900&key=total, Accessed on (2025)."},{"key":"3620_CR2","unstructured":"National Cancer Center, Cancer information service, Cancer registry and statistics, https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html, Accessed on (2025)."},{"key":"3620_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","volume":"23","author":"T Moriwaki","year":"2018","unstructured":"Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, et al. Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum multicenter observational study. Oncologist. 2018;23:7\u201315.","journal-title":"Oncologist"},{"key":"3620_CR4","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1634\/theoncologist.2017-0573","volume":"23","author":"C Cremolini","year":"2018","unstructured":"Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, et al. Trifluridine\/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018;23:1178\u201387.","journal-title":"Oncologist"},{"key":"3620_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 2017;18:1172\u201381.","journal-title":"Lancet Oncol"},{"key":"3620_CR6","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s10147-022-02243-4","volume":"27","author":"H Matsuoka","year":"2022","unstructured":"Matsuoka H, Yamada T, Ohta R, Yoshida Y, Watanabe T, Takahashi M, et al. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). Int J Clin Oncol. 2022;27:1859\u201366.","journal-title":"Int J Clin Oncol"},{"key":"3620_CR7","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","volume":"25","author":"H Satake","year":"2020","unstructured":"Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, et al. Phase Ib\/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). Oncologist. 2020;25:e1855\u201363.","journal-title":"Oncologist"},{"key":"3620_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10147-020-01794-8","volume":"26","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol. 2021;26:111\u20137.","journal-title":"Int J Clin Oncol"},{"key":"3620_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412\u201320.","journal-title":"Lancet Oncol"},{"key":"3620_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367.","journal-title":"N Engl J Med"},{"key":"3620_CR11","unstructured":"NCCN Clinical Practice Guidelines in Oncology for Colon Cancer (version 5 (2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf, accessed on 2025 Nov 2."},{"key":"3620_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","volume":"35","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Martinelli E. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO metastatic colorectal cancer living guideline. Ann Oncol. 2023;35:241\u20133.","journal-title":"Ann Oncol"},{"key":"3620_CR13","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1002\/cam4.4599","volume":"11","author":"T Kawakami","year":"2022","unstructured":"Kawakami T, Masuishi T, Kawamoto Y, Go H, Kato K, Kumanishi R, et al. The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: a multicenter retrospective study. Cancer Med. 2022;11:2184\u201392.","journal-title":"Cancer Med"},{"key":"3620_CR14","first-page":"16","volume":"7","author":"FA Zeineddine","year":"2023","unstructured":"Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis. Oncol. 2023;7:16.","journal-title":"Oncol"},{"key":"3620_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402:41\u201353.","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03620-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:37:23Z","timestamp":1790692643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03620-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":15,"alternative-id":["3620"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03620-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Kawakami declares honoraria from Bristol Myers Squibb, Ono Pharmaceutical. TH declares consulting fee from 22cemit and honoraria from Kyorin Pharmaceutical and Meiji Pharmaceutical. TM declares consulting fees from Nippon Kayaku, honoraria from Takeda, Chugai, Merck Bio Pharma, Taiho, Bayer, Lilly Japan, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono Pharmaceutical, Bristol Myers Squibb, Nippon Kayaku, MSD, Takata, Guardant Health, Amgen; institutional grant from MSD, Daiichi Sankyo, Ono Pharmaceutical, Novartis, Amgen, Syneos Healthe Clinical, Boehringer-Ingelheim, Pfizer, Cimic Shift Zero, Eli Lilly, Abbvie, Merck Biopharma. TH declares consulting fee from 22cemit and Chugai Pharmaceutical and honoraria from Kyorin Pharmaceutical and Meiji Pharmaceutical. SM declares honoraria from Taiho Pharmaceutical, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo and advisory board from Chugai Pharmaceutical. YH declares honoraria from Taiho Pharmaceutical. TA declares honoraria from Daiichi Sankyo, Taiho Pharmaceutical, Eli Lilly Japan, Astellas Pharma, Bristol Myers Squibb, Merck & Co. NT declares honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb. SB declares honoraria from Ono Pharmaceutical, Brystol Meyers Squibb, MSD, and advisory board from Amgen. TE declares honoraria from Chugai, Taiho, Ono Pharmaceutical, Hisamitsu, Roche Diagnostics, Zeria, MSD, Eli Lilly, Daiichi Sankyo, and consulting fees from Takeda; institutional grant\/research support from Ono Pharmaceutical, Seagen, Taiho, Jazz Pharmaceuticals, Ignyta, Quintiles, Bristol Myers Squibb, Asahikasei Pharma, ALX Oncology, MSD, Nihon Kayaku, Astellas Pharma, Astellas Amgen Biopharma, IQVIA, Daiichi Sankyo, Chugai Pharmaceutical, Syneos Health Clinical, Pfizer, Amgen. K. Yamamoto declared research funding from Otsuka Pharmaceutical Co., Ltd, CHUGAI PHARMACEUTICAL CO., LTD, Kyowa Kirin Co. Ltd., Euro Doctor Concierge, LLC, DAIICHI SANKYO COMPANY, LIMITED, TERUMO CORPORATION, TAIHO Phamaceutical Co., Ltd., consulting fee from SYSMEX CORPORATION, Delta-Fly Pharma, Shockwave Medical Japan, and honoraria for lectures from FUJIFILM Toyama Chemical Co., Ltd., CMIC CO.,Ltd. DAIICHI SANKYO COMPANY, LIMITED, TME Therapeutics Inc., Takeda Pharmaceutical Company Limited, CM Plus Corporation., AstraZeneca plc, CHUGAI PHARMACEUTICAL CO.,LTD. SY declared honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., MSD K.K., Bayer Yakuhin Ltd., Merck Biopharma Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Roche Diagnostics K.K., Nippon Boehringer Ingelheim Co., Ltd., and MIYARISAN Pharmaceutical Co., Ltd. HS declares consulting fees from Kyo Diagnostics, honoraria from Daiichi Sankyo Co, Ltd, MSD Co, Ltd, Ono Pharmaceutical Co, Ltd, Taiho Pharmaceutical Co, Ltd, Takeda Pharmaceutical Co, Ltd, Astellas Pharma, AstraZeneca plc, Bristol-Myers Squibb Co, Ltd, Chugai Pharmaceutical Co, Ltd, Eli Lilly Japan Co, Ltd, Merck Bio Pharma Co, Ltd, Yakult Honsha Co, Ltd (Takata Pharmaceutical Co. Ltd.), and grants support from Asahi Kasei, Kyo Diagnostics, and MSD, K. Yamazaki declared honoraria from Chugai Pharma, Daiichi Sankyo, Yakult Honsha, Takeda, Merck Serono, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical, MSD, Bristol Myers Squibb. EO declares grants from Guardant Health, and honoraria from Eli Lilly, Takeda Pharmaceutical, Ono Pharmaceutical, Bristol Meyers Squibb. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Kyushu University IRB (2020-305). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}